Top 6 Questions in Diabetes

Learning Objectives

  • Identifying and selecting an add-on to metformin therapy in people with type 2 diabetes  – both with and without established cardiovascular disease
  • Exploring whether South Asian patients with type 2 diabetes have an incretin defect and the potential implications.
  • Considering adverse effects and contraindications when using an SGLT2 inhibitor.
  • Gaining perspective from both the Endocrinologist and Nephrologist on antihyperglycemic agents and renal protection and renal dosing of agents in type 2 diabetes.
  • Identifying whether there is still a role for initiating sulfonylureas and when you would stop them.

Agenda

Click to See Video in Chapters


00:00:00
Welcome and Opening Remarks
Dr. Ronald Goldenberg – Chair

00:02:38
Question #1: What is my preferred add-on to metformin therapy in people with type 2 diabetes without established cardiovascular disease and how do you decide?
Dr. Ronald Goldenberg

00:12:53
Question #2: What is my preferred add-on to metformin therapy in people with type 2 diabetes with established cardiovascular disease and why?
Dr. Subodh Verma

00:30:01
Question #3: Do South Asian patients with type 2 diabetes have an incretin defect? What are the potential implications of this?
Dr. Subodh Verma

00:38:51
Question #4: What adverse effects and contraindications need to be considered when using an SGLT2 inhibitor?
Dr. Harpreet Bajaj

00:52:13
Question #5: Antihyperglycemic agents and renal protection and renal dosing of agents in type 2 diabetes? Perspectives from the Endocrinologist and Nephrologist
Dr. Ronald Goldenberg and Dr. Jordan Weinstein

01:06:29
Question #6: Is there still a role for initiating sulfonylureas? When would you stop a sulfonylurea? A case illustration.
Dr. Ronald Goldenberg and Dr. Harpreet Bajaj

01:19:32
Closing Remarks

Faculty

Ronald M Goldenberg
MD, FRCPC, FACE
Consultant Endocrinologist, North York General Hospital
and LMC Diabetes & Endocrinology

Subodh Verma
MD, PhD, FRCSC, FAHA
Division of Cardiac Surgery, St. Michael’s Hospital
Professor Surgery and Pharmacology & Toxicology, University of Toronto

Harpreet Singh Bajaj
MD, MPH, ECNU, FACE
Clinical Endocrinologist, LMC Diabetes & Endocrinology, Brampton
Tariff Chairman, Section of Endocrinology, Ontario Medical Association
Founding Chairman, “STOP Diabetes” Foundation Inc.

Jordan Weinstein
MD, FRCPC
Division of Nephrology, St. Michael’s Hospital
Assistant Professor of Medicine, University of Toronto
Director, UKidney.com

Video Information
  • Credit:No Credit Available
  • Post Date:December 30, 2016
  • Expiry Date:N/A

Related Videos